Myia is a data driven operating system for virtual care. Myia equips Patients and Clinicians with the tools needed for the patients transition from hospital at home, to 30 day readmit avoidance, to traditional RPM. The shift to value-based reimbursement models necessitates more preventative models of care, Myia's platform crosses these models and facilitates cost savings. Myia is partnering with the leading healthcare organizations around the country. Partners like Mercy Virtual, one of the country's leaders in continuous and preventative chronic care management, including patients with Heart Failure, COPD, Diabetes, and Hypertension. Myia improves quality of life for patients and predicts and prevents costly medical events for care providers. Myia takes a device agnostic approach to daily patient monitoring, applies proprietary machine learning for smart triage, and has a clinician centric application to surface the right patient at the right time into workflow. Partnerships with BioIntellisense and Dispatch health bring a complete Hospital at Home offering to the market.

• eCART is a research-based, AI-driven software as a medical device (SaMD) that utilizes a machine learning algorithm to continuously assess hospitalized patients’ risk of impending death or intensive care unit (ICU) transfer, assisting medical staff in swift and accurate recognition of patients requiring increased medical attention. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts likelihood of critical illness onset, hours before it happens.
• eCART received FDA 510(k) clearance in 2024, with clinical performance data of nearly two million hospitalizations from 21 hospitals, including an unprecedented level of real-world prospective data, to ensure consistent accuracy across geography, age, race, and top medical conditions (e.g. sepsis, COPD, heart failure). 
• Built upon more than a decade of ongoing scientific research, eCART was developed at UChicago Medicine by Dr. Dana Edelson, MD, MS and Dr. Matthew Churpek, MD, PhD and is well chronicled in published literature. The analytic and workflow have been in use in clinical practice since 2016.

At AgileMD, we are building the most advanced real-time predictive analytics and clinical pathways platform for hospitals.

To date, AgileMD tools have been used on more than 4 million patient encounters by more than 135,000 clinical users in over 250 hospitals, including some of the nation's leading academic medical centers. AgileMD's eCART clinical deterioration prediction software is FDA cleared and the first AI-powered early warning device for ward patients to go through the FDA process with real-world prospective data. 

AgileMD is backed by premier start-up partners MATTER, YCombinator, and Rock Health, and our cutting-edge analytics are built on more than decade of ongoing research at the University of Chicago. In 2021, AgileMD garnered nearly $3 million in combined federal research and development funding from the U.S. Department of Health and Human Services (HHS), including the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).

There are no homegrown options that do all that Myia is capable of from a Clinical Perspective. Myia can be used to monitor patient data in four major settings, Inpatient, Hospital at Home, 30 Day readmit avoidance programs, long term RPM programs.

Myia is the only RPM vendor that we are aware of with Data Scientist on staff as well as Data Analyst who work to stratify data and work with Clients to maximize the value of the Myia platform. By looking across patients clinical indication Myia can predict who should be on the program as well as whom is likely to require a hospital visit. These analytics help reduce costs and patient outcomes.

• Continuously monitors EHR data in real time
• Stratifies hospitalized patients by risk of impending all-cause clinical deterioration and sepsis
• Notifies inpatient providers when patient may need additional assessment and management
• Recommends clinical pathways with integrated order entry

• Authorized: FDA 510(k) cleared
• Tested: Derived and validated in nearly 3 million patient encounters across 28 hospitals
• Experienced: 8+ years in clinical use; 10+ years of published academic literature on value over other early warning scores
• Accurate: High sensitiviy and specificity, meaning fewer false alarms and more efficient focus on the highest risk patients
• Integrated: Embedded cross-team workflow ensures that risk scores are not ignored and action is taken
• Benchmarked: Robust reporting, benchmarking, and implementation support drive quality improvement